Mitochondrial Apoptosis: Killing Cancer Using the Enemy Within

Overview

Journal Br J Cancer

Specialty Oncology

Date 2015 Mar 6

PMID 25742467

Citations 306

Authors

J Lopez

S W G Tait

Affiliations

Soon will be listed here.

Abstract

Apoptotic cell death inhibits oncogenesis at multiple stages, ranging from transformation to metastasis. Consequently, in order for cancer to develop and progress, apoptosis must be inhibited. Cell death also plays major roles in cancer treatment, serving as the main effector function of many anti-cancer therapies. In this review, we discuss the role of apoptosis in the development and treatment of cancer. Specifically, we focus upon the mitochondrial pathway of apoptosis-the most commonly deregulated form of cell death in cancer. In this process, mitochondrial outer membrane permeabilisation or MOMP represents the defining event that irrevocably commits a cell to die. We provide an overview of how this pathway is regulated by BCL-2 family proteins and describe ways in which cancer cells can block it. Finally, we discuss exciting new approaches aimed at specifically inducing mitochondrial apoptosis in cancer cells, outlining their potential pitfalls, while highlighting their considerable therapeutic promise.

Citing Articles

Essential Oils from Citrus Peels Promote Calcium Overload-Induced Calcicoptosis in U251 Cells.

Li Y, Wei J, Ye Z, Ji C, Li W, Xu L Antioxidants (Basel). 2025; 14(1.

PMID: 39857347 PMC: 11762846. DOI: 10.3390/antiox14010011.

TRIM25: A Global Player of Cell Death Pathways and Promising Target of Tumor-Sensitizing Therapies.

Eberhardt W, Nasrullah U, Pfeilschifter J Cells. 2025; 14(2).

PMID: 39851496 PMC: 11764315. DOI: 10.3390/cells14020065.

Regulation of reactive oxygen species and the role of mitochondrial apoptotic-related genes in rheumatoid arthritis.

Gao C, Zhang C, Wen L, Zhang G, Liu X, Wang J Sci Rep. 2025; 15(1):2165.

PMID: 39820483 PMC: 11739689. DOI: 10.1038/s41598-025-85460-x.

Antioxidant, Anti-Inflammatory, and Anticancer Activities of Five Citrus Peel Essential Oils.

Li Y, Li W, Ye Z, Ji C, Zhou Z Antioxidants (Basel). 2025; 13(12.

PMID: 39765890 PMC: 11672981. DOI: 10.3390/antiox13121562.

Doublecortin regulates the mitochondrial-dependent apoptosis in glioma via Rho-A/Net-1/p38-MAPK signaling.

Nadeem I, Han Z, Xiaoliang H, Adzraku S, Kambey P, Kanwore K Mol Med. 2024; 30(1):272.

PMID: 39719558 PMC: 11668075. DOI: 10.1186/s10020-024-01021-4.

References

Martinou I, Desagher S, Eskes R, Antonsson B, Andre E, Fakan S . The release of cytochrome c from mitochondria during apoptosis of NGF-deprived sympathetic neurons is a reversible event. J Cell Biol. 1999; 144(5):883-9. PMC: 2148194. DOI: 10.1083/jcb.144.5.883. View

Sarosiek K, Chi X, Bachman J, Sims J, Montero J, Patel L . BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. Mol Cell. 2013; 51(6):751-65. PMC: 4164233. DOI: 10.1016/j.molcel.2013.08.048. View

Certo M, Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong S . Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006; 9(5):351-65. DOI: 10.1016/j.ccr.2006.03.027. View

van Delft M, Wei A, Mason K, Vandenberg C, Chen L, Czabotar P . The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006; 10(5):389-99. PMC: 2953559. DOI: 10.1016/j.ccr.2006.08.027. View

Smit L, Hallaert D, Spijker R, De Goeij B, Jaspers A, Kater A . Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood. 2006; 109(4):1660-8. DOI: 10.1182/blood-2006-05-021683. View

Colell A, Ricci J, Tait S, Milasta S, Maurer U, Bouchier-Hayes L . GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation. Cell. 2007; 129(5):983-97. DOI: 10.1016/j.cell.2007.03.045. View

Taylor R, Cullen S, Martin S . Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2007; 9(3):231-41. DOI: 10.1038/nrm2312. View

Tse C, Shoemaker A, Adickes J, Anderson M, Chen J, Jin S . ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008; 68(9):3421-8. DOI: 10.1158/0008-5472.CAN-07-5836. View

Hallaert D, Jaspers A, van Noesel C, van Oers M, Kater A, Eldering E . c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood. 2008; 112(13):5141-9. DOI: 10.1182/blood-2008-03-146704. View

10.

Vogler M, Butterworth M, Majid A, Walewska R, Sun X, Dyer M . Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood. 2008; 113(18):4403-13. DOI: 10.1182/blood-2008-08-173310. View

11.

Lartigue L, Kushnareva Y, Seong Y, Lin H, Faustin B, Newmeyer D . Caspase-independent mitochondrial cell death results from loss of respiration, not cytotoxic protein release. Mol Biol Cell. 2009; 20(23):4871-84. PMC: 2785731. DOI: 10.1091/mbc.e09-07-0649. View

12.

Garzon R, Heaphy C, Havelange V, Fabbri M, Volinia S, Tsao T . MicroRNA 29b functions in acute myeloid leukemia. Blood. 2009; 114(26):5331-41. PMC: 2796138. DOI: 10.1182/blood-2009-03-211938. View

13.

Beroukhim R, Mermel C, Porter D, Wei G, Raychaudhuri S, Donovan J . The landscape of somatic copy-number alteration across human cancers. Nature. 2010; 463(7283):899-905. PMC: 2826709. DOI: 10.1038/nature08822. View

14.

Tait S, Parsons M, Llambi F, Bouchier-Hayes L, Connell S, Munoz-Pinedo C . Resistance to caspase-independent cell death requires persistence of intact mitochondria. Dev Cell. 2010; 18(5):802-13. PMC: 3004027. DOI: 10.1016/j.devcel.2010.03.014. View

15.

Tait S, Oberst A, Quarato G, Milasta S, Haller M, Wang R . Widespread mitochondrial depletion via mitophagy does not compromise necroptosis. Cell Rep. 2013; 5(4):878-85. PMC: 4005921. DOI: 10.1016/j.celrep.2013.10.034. View

16.

Tait S, Ichim G, Green D . Die another way--non-apoptotic mechanisms of cell death. J Cell Sci. 2014; 127(Pt 10):2135-44. PMC: 4021468. DOI: 10.1242/jcs.093575. View

17.

Fresquet V, Rieger M, Carolis C, Garcia-Barchino M, Martinez-Climent J . Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood. 2014; 123(26):4111-9. DOI: 10.1182/blood-2014-03-560284. View

18.

Ng S, Davids M . Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2014; 12(4):224-9. View

19.

Gama V, Swahari V, Schafer J, Kole A, Evans A, Huang Y . The E3 ligase PARC mediates the degradation of cytosolic cytochrome c to promote survival in neurons and cancer cells. Sci Signal. 2014; 7(334):ra67. PMC: 4182917. DOI: 10.1126/scisignal.2005309. View

20.

Lemke J, von Karstedt S, Zinngrebe J, Walczak H . Getting TRAIL back on track for cancer therapy. Cell Death Differ. 2014; 21(9):1350-64. PMC: 4131183. DOI: 10.1038/cdd.2014.81. View